Table 3.

HPV16 and HPV18 antibody stability between months 24, 36, and 48 by number of doses

1-dose2-doses(0/1)2-doses(0/6)3-doses
(Stable between 24–48 month)
n (%)
HPV16
Stable67 (85.90)137 (97.86)52 (100)119 (99.17)
Increase11 (14.10)3 (2.14)01 (0.83)
HPV18
Stable74 (94.87)133 (95.00)52 (100)120 (100)
Increase4 (5.13)7 (5.00)00
(Stable between 36–48 month)
n (%)
HPV16
Stable72 (92.31)136 (97.14)52 (100)119 (99.17)
Increase6 (7.69)4 (2.86)01 (0.83)
HPV18
Stable75 (96.15)137 (97.86)51 (98.08)117 (97.50)
Increase3 (3.85)3 (2.14)1 (1.92)3 (2.50)

HPV16 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.88 (P < 0.0001).

HPV18 Spearman's rank correlation coefficient at 24- and 48-month visits was 0.90 (P < 0.0001).